Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:12:56 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:VRDN - VIRIDIAN THERAPEUTICS INC - https://www.viridiantherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRDN - Q0.114.41·19.530.116.52-0.53-3.1511.58,0358,63017.29  17.33  16.46527.20  9.9017:45:39Jul 0315 min RT 2¢

Recent Trades - Last 10 of 8630
Time ETExPriceChangeVolume
17:45:39Q16.52-0.5313,047
16:20:00Q16.52-0.53868
16:04:15Q16.52-0.531
16:04:03Q16.52-0.531
16:04:03Q16.52-0.531
16:02:54Q16.52-0.53185
16:02:54Q16.52-0.5315
16:02:36Q16.52-0.5390
16:02:04Q16.52-0.533,327
16:02:04Q16.52-0.53233

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-03 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-06-05 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-30 07:00U:VRDNNews ReleaseViridian Therapeutics to Participate in Upcoming June Investor Conferences
2025-05-20 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
2025-05-07 16:15U:VRDNNews ReleaseViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
2025-05-06 07:00U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
2025-05-02 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-04-07 07:00U:VRDNNews ReleaseViridian Therapeutics Appoints Jeff Ajer to its Board of Directors
2025-03-10 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 07:00U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-06 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-08 07:00U:VRDNNews ReleaseViridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
2024-12-16 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
2024-12-13 18:00U:VRDNNews ReleaseViridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
2024-12-04 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-12 07:00U:VRDNNews ReleaseViridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
2024-11-05 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-11 23:25U:VRDNNews ReleaseViridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
2024-09-10 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
2024-09-10 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease